TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has announced the quotation of 150,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective November 25, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve market liquidity, which could positively impact its operations and industry positioning.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.20 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in the market.
YTD Price Performance: 45.20%
Average Trading Volume: 523,903
Technical Sentiment Signal: Buy
Current Market Cap: A$2.3B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.